Drug-Eluting Balloon Catheters Market Size By Product (Coronary Artery Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}, Peripheral Vascular Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}), By End-use (Hospitals and Clinics,

Drug-Eluting Balloon Catheters Market Size By Product (Coronary Artery Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}, Peripheral Vascular Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}), By End-use (Hospitals and Clinics, Ambulatory Surgical Centers, Catheterization Laboratories), Industry Analysis Report, Regional Outlook, Application Potential, Covid-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2028

The drug-eluting balloon catheters market is set to witness significant growth by 2028 owing to increasing advancements in product technology. In addition, rising demand for minimally invasive medical surgeries, coupled with mounting occurrences of chronic disorders, is likely to further impel industry expansion through the forecast period.

Recently, key industry players have been focusing on the development of economical and precise drug-eluting balloon catheters that are effective in improving medication delivery, which has fostered drug-eluting balloon catheters market growth significantly. For instance, in August 2019, B. Braun, an expert in interventional procedures and a part of B. Braun Group of Companies, received the U.S. Food and Drug Administration’s breakthrough device designation for its SeQuent Please ReX drug-coated PTCA balloon stent in treating coronary in-stent restenosis (ISR).

Similarly, in November 2021, Biosensors International Group Ltd., a medical devices firm, that its Biolimus drug-coated balloon catheters showed effective experimental results in small coronary vessels tested during the BIO-RISE CHINA study. It has been proclaimed as a new therapeutic option for the treatment of small vessel coronary artery disease for patients undergoing PCI.

Notably, the COVID-19 pandemic has imposed a huge threat to people’s health worldwide, particularly affecting those with underlying heart diseases. This has led to an unprecedented surge in treatment innovations to find efficient solutions to the viral infection, which has positively impacted the product scenario. To that effect, in April 2022, Medtronic, a leading medical devices firm, announced that its Symplicity Spyral RDN (renal denervation) system showed clinically significant and durable blood pressure reductions over three years in patients who were prescribed medication.

The drug-eluting balloon catheters sector has been divided based on end-use, product, and region. In terms of product, the industry has been further segregated into peripheral vascular disease & coronary artery disease drug-eluting balloon catheters.

Among the two, in 2021, drug-eluting balloon catheters for peripheral vascular diseases held the lion's share in the industry with a revenue of more than USD 251 million and are projected to develop at a robust pace over 2022-2028 on account of surging incidences of peripheral vascular disorders globally.

In terms of end-use, the drug-eluting balloon catheters market has been categorized into catheterization laboratories, hospital and clinics, and ambulatory surgical centers. The hospital and clinics segment are anticipated to witness notable growth to reach more than USD 522 million in revenue by 2028 owing to growing healthcare spending, increasing hospital admissions, and surge in usage of these devices in hospitals.

With respect to region, the North America drug-eluting balloon catheters market surpassed USD 200 million valuation in 2021 and is poised to witness steady progress over the forecast timeline. Growing product adoption is set to bolster product uptake across countries in the region in the forthcoming years.